Soluble TWEAK independently predicts atherosclerosis in renal transplant patients

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Turkmen, Kultigin ^a   Tonbul, Halil Zeki ^b   Erdur, Fatih Mehmet ^b   Toker, Aysun ^b   Biyik, Zeynep ^b   Ozbiner, Huseyin ^b   Gaipov, Abduzhappar ^b   Gul, Elvin Enes ^b   Kayrak, Mehmet ^b   Solak, Yalcin ^b   Ozbek, Orhan ^b   Turk, Suleyman ^b   Covic, Adrian ^c  

^a ERZINCAN UNIVERSITY   (Turkey)

^b NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

^c C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

Carotid intima media thickness; Neutrophil to lymphocyte ratio; Renal transplantation; sTWEAK

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CALCIUM; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; UREA; URIC ACID;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CALCIUM BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SOLUBILITY; TUMOR NECROSIS FACTORS;

EID: 84880288779     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-144     Document Type: Article

References (35)

1. Cardiovascular mortality in end-stage renal disease. Collins AJ, Am J Med Sci 2003 325 4 163 7 10.1097/00000441-200304000-00002 12695721 (Pubitemid 36437989)
2. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG, Kidney Int 2000 57 3 1100 6 10.1046/j.1523-1755.2000.00937.x 10720962 (Pubitemid 30434799)
3. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, Nephrol Dial Transplant 2005 20 6 1048 56 10.1093/ndt/gfh813 15814534 (Pubitemid 40862092)
4. Outcome and risk factors for left ventricular disorders in chronic uraemia. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE, Nephrol Dial Transplant 1996 11 7 1277 85 8672023 (Pubitemid 26241416)
5. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Kidney Int 2000 58 1 353 62 10.1046/j.1523-1755.2000.00173.x 10886582 (Pubitemid 30429882)
6. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. Muntner P, He J, Astor BC, Folsom AR, Coresh J, J Am Soc Nephrol 2005 16 2 529 38 10.1681/ASN.2004080656 15625072 (Pubitemid 41725151)
7. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM, Kidney Int 2002 62 5 1524 38 10.1046/j.1523-1755.2002.00600.x 12371953 (Pubitemid 35286260)
8. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z, Clin J Am Soc Nephrol 2008 3 2 505 21 10.2215/CJN.03670807 18184879
9. Fetuin-A, inflammation, and coronary artery calcification in hemodialysis patients. Turkmen K, Gorgulu N, Uysal M, Ozkok A, Sakaci T, Unsal A, et al. Indian J Nephrol 2011 21 2 90 4 10.4103/0971-4065.82128 21769170
10. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS, Am J Cardiol 2008 102 6 653 7 10.1016/j.amjcard. 2008.05.006 18773982
11. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Nunez J, Nunez E, Bodi V, Sanchis J, Minana G, Mainar L, et al. Am J Cardiol 2008 101 6 747 52 10.1016/j.amjcard.2007.11.004 18328833
12. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ, J Surg Oncol 2005 91 3 181 4 10.1002/jso.20329 16118772 (Pubitemid 41254421)
13. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL, Am J Cardiol 2006 97 7 993 6 10.1016/j.amjcard.2005.10.034 16563903
14. The Relationship Between Neutrophil-to-Lymphocyte Ratio and Inflammation in End-Stage Renal Disease Patients. Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ, Ren Fail 2012 34 2 155 9 22172001
15. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Burkly LC, Michaelson JS, Zheng TS, Immunol Rev 2011 244 1 99 114 10.1111/j.1600-065X.2011.01054.x 22017434
16. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Wiley SR, Winkles JA, Cytokine Growth Factor Rev 2003 14 3-4 241 9 12787562 (Pubitemid 36693144)
17. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T, J Biol Chem 2003 278 34 32317 23 10.1074/jbc.M302518200 12794080 (Pubitemid 37048427)
18. Considering TWEAK as a target for therapy in renal and vascular injury. Ortiz A, Sanz AB, Munoz Garcia B, Moreno JA, Sanchez Nino MD, Martin-Ventura JL, et al. Cytokine Growth Factor Rev 2009 20 3 251 8 10.1016/j.cytogfr.2009.05.002 19482507
19. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, et al. Atherosclerosis 2011 219 2 892 9 10.1016/j.atherosclerosis.2011.09.016 21962403
20. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, Michel JB, et al. Arterioscler Thromb Vasc Biol 2007 27 4 916 22 10.1161/01.ATV. 0000258972.10109.ff 17272745 (Pubitemid 46606725)
21. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, et al. Clin J Am Soc Nephrol 2011 6 4 785 92 10.2215/CJN.09231010 21330486
22. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 6 499 502 4337382
23. Creatinine filtration, secretion and excretion during progressive renal disease. Modification of Diet in Renal Disease (MDRD) Study Group. Levey AS, Berg RL, Gassman JJ, Hall PM, Walker WG, Kidney Int Suppl 1989 27 73 80 2636677
24. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C, J Am Soc Nephrol 2001 12 11 2458 64 11675423 (Pubitemid 33021124)
25. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, et al. Kidney Int 2006 70 10 1750 8 10.1038/sj.ki.5001866 17003819 (Pubitemid 44684806)
26. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, et al. Clin J Am Soc Nephrol 2009 4 11 1716 23 10.2215/CJN.02760409 19820131
27. Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. Yilmaz MI, Qureshi AR, Carrero JJ, Saglam M, Suliman ME, Caglar K, et al. Am J Nephrol 2010 31 3 214 21 10.1159/000272936 20068285
28. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. Gungor O, Kismali E, Sisman AR, Kircelli F, Carrero JJ, Tatar E, et al. Ren Fail 2013 35 1 77 81 10.3109/0886022X.2012.734890 23101788
29. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, Heimburger O, et al. Clin J Am Soc Nephrol 2009 4 1 110 8 10.2215/CJN.02790608 18945991
30. Mechanisms of rejection: current perspectives. Wood KJ, Goto R, Transplantation 2012 93 1 1 10 10.1097/TP.0b013e31823cab44 22138818
31. Kidney transplantation improves arterial function measured by pulse wave analysis and endothelium-independent dilatation in uraemic patients despite deterioration of glucose metabolism. Hornum M, Clausen P, Idorn T, Hansen JM, Mathiesen ER, Feldt-Rasmussen B, Nephrol Dial Transplant 2011 26 7 2370 7 10.1093/ndt/gfq704 21097648
32. Seyahi N, Cebi D, Altiparmak MR, Akman C, Ataman R, Pekmezci S, et al Nephrol Dial Transplant: Progression of coronary artery calcification in renal transplant recipients 2011
33. The cytokine TWEAK modulates renal tubulointerstitial inflammation. Sanz AB, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, Kreztler M, et al. J Am Soc Nephrol 2008 19 4 695 703 10.1681/ASN.2007050577 18235096
34. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Yoshino T, Nakase H, Honzawa Y, Matsumura K, Yamamoto S, Takeda Y, et al. Inflamm Bowel Dis 2010 16 12 2022 33 10.1002/ibd.21318 20848491
35. Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response. Du S, Hiramatsu N, Hayakawa K, Kasai A, Okamura M, Huang T, et al. J Immunol 2009 182 11 7201 11 10.4049/jimmunol.0801772 19454717